PALLAS 311 nm UVB laser treatment for vitiligo, psoriasis, alopecia areata, and atopic dermatitis
Study of the Effectiveness of the PALLAS Laser in the Treatment of Skin Diseases That Respond Well to UV Light
This study will test the PALLAS 311 nm UVB laser as an in-clinic, twice-weekly treatment for adults with vitiligo, psoriasis, alopecia areata, or atopic dermatitis for up to three months.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Szeged University Academic / other |
| Locations | 1 site (Szeged, Csongrád-Csanád Vármegye) |
| Trial ID | NCT07250997 on ClinicalTrials.gov |
What this trial studies
This is a single-center, prospective clinical evaluation of the CE-marked PALLAS 311 nm solid-state UVB laser used on skin areas such as the face, hands, arms, feet, or legs. Adult patients with skin conditions expected to respond to targeted UVB will receive two approximately 10-minute laser sessions per week for up to three months, with photographic documentation at baseline and monthly. Investigators will record clinical responses and patients will complete a Patient Satisfaction Scale at study end, while also providing feedback on the device's user-friendliness. The study excludes minors, pregnant people, those with epilepsy, active infection or fever, and participants currently in other trials.
Who should consider this trial
Good fit: Ideal candidates are adults with vitiligo, psoriasis, alopecia areata, or atopic dermatitis that is expected to respond to targeted UVB, who can attend twice-weekly clinic visits and provide informed consent.
Not a fit: Patients under 18, pregnant people, those with epilepsy, active infections or fever, or skin disease unlikely to respond to targeted UVB are unlikely to benefit from this intervention.
Why it matters
Potential benefit: If successful, the PALLAS laser could offer a stable, effective, low-maintenance localized UVB option that shortens treatment sessions and reduces the risk of unpredictable dosing or burns.
How similar studies have performed: Targeted 311 nm UVB and excimer laser treatments have shown benefit for these conditions in prior studies, while the PALLAS device itself represents a newer implementation of that approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. The subject understands the information provided, gives informed consent to participate in the study and is deemed by the investigator to be able to participate, 2. a skin condition that is expected to respond well to targeted UVB treatment, 3. a signed consent form. Exclusion Criteria: 1. Patient under 18 years of age, 2. pregnancy 3. epilepsy, 4. fever, infectious diseases, 5. the patient is within one month or currently enrolled in another clinical trial.
Where this trial is running
Szeged, Csongrád-Csanád Vármegye
- University of Szeged, Albert Szent-Györgyi Clinical Centre, Department of Dermatology and Allergology — Szeged, Csongrád-Csanád Vármegye, Hungary (Recruiting)
Study contacts
- Study coordinator: Lajos Kemény, professor, MD, DSc, MHAS
- Email: kemeny.lajos@med.u-szeged.hu
- Phone: +36305152884
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.